AP Biosciences Inc (6945.TWO)

TWD 49.6

(0.51%)

Market Cap (In TWD)

4.21 Billion

Revenue (In TWD)

32.25 Million

Net Income (In TWD)

-339.29 Million

Avg. Volume

40.92 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
41.5-70.0
PE
-
EPS
-
Beta Value
0.0
ISIN
TW0006945009
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jeng-Horng Her Ph.D.
Employee Count
-
Website
https://www.apbioinc.com
Ipo Date
2023-07-14
Details
AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. The company was founded in 2013 and is based in Taipei City, Taiwan.